NMTC (NeuroOne Medical Technologies) Piotroski F-Score: 4 (As of Jun. 26, 2026) — Near Median


NMTC NeuroOne Medical Technologies Corp NMTC
43 GF Score
Price $3.25
GF Value $6.58
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies Piotroski F-Score?

NeuroOne Medical Technologies NMTC -4.04% 43 Piotroski F-Score is 4 as of Jun. 26, 2026, which is at its 10-year median of 4.00. GuruFocus rates NMTC with a GF Score™ of 43/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 56.52% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroOne Medical Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for NeuroOne Medical Technologies's Piotroski F-Score or its related term are showing as below:

NMTC' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 4

During the past 13 years, the highest Piotroski F-Score of NeuroOne Medical Technologies was 6. The lowest was 2. And the median was 4.

NeuroOne Medical Technologies  (NAS:NMTC) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NeuroOne Medical Technologies Piotroski F-Score Related Terms


NeuroOne Medical Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies Piotroski F-Score Chart

NeuroOne Medical Technologies Annual Data
Trend Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 5.00 3.00 6.00

NeuroOne Medical Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 6.00 6.00 6.00 4.00

NMTC vs CTSO, CODX, PETV: Piotroski F-Score Comparison

For the Medical Devices subindustry, NeuroOne Medical Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroOne Medical Technologies Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Piotroski F-Score falls into.


NMTC
43GF Score
NeuroOne Medical Technologies Corp NMTC
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was -1.501 + -1.619 + -1.438 + -2.086 = $-6.64 Mil.
Cash Flow from Operations was -1.464 + -1.526 + -3.116 + -1.329 = $-7.44 Mil.
Revenue was 1.696 + 2.741 + 2.893 + 2.391 = $9.72 Mil.
Gross Profit was 0.915 + 1.529 + 1.568 + 1.287 = $5.30 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(4.457 + 10.819 + 10.786 + 8.578 + 7.865) / 5 = $8.501 Mil.
Total Assets at the begining of this year (Mar25) was $4.46 Mil.
Long-Term Debt & Capital Lease Obligation was $0.09 Mil.
Total Current Assets was $7.40 Mil.
Total Current Liabilities was $1.69 Mil.
Net Income was -2.768 + -3.351 + 1.785 + -2.271 = $-6.61 Mil.

Revenue was 0.826 + 0.272 + 3.274 + 1.387 = $5.76 Mil.
Gross Profit was 0.282 + 0.141 + 1.927 + 0.771 = $3.12 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5.395 + 4.913 + 5.37 + 6.494 + 4.457) / 5 = $5.3258 Mil.
Total Assets at the begining of last year (Mar24) was $5.40 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
Total Current Assets was $3.75 Mil.
Total Current Liabilities was $1.76 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroOne Medical Technologies's current Net Income (TTM) was -6.64. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeuroOne Medical Technologies's current Cash Flow from Operations (TTM) was -7.44. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-6.644/4.457
=-1.4906888

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-6.605/5.395
=-1.22428174

NeuroOne Medical Technologies's return on assets of this year was -1.4906888. NeuroOne Medical Technologies's return on assets of last year was -1.22428174. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NeuroOne Medical Technologies's current Net Income (TTM) was -6.64. NeuroOne Medical Technologies's current Cash Flow from Operations (TTM) was -7.44. ==> -7.44 <= -6.64 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0.092/8.501
=0.01082226

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0.207/5.3258
=0.0388674

NeuroOne Medical Technologies's gearing of this year was 0.01082226. NeuroOne Medical Technologies's gearing of last year was 0.0388674. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=7.404/1.689
=4.38365897

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3.754/1.763
=2.12932501

NeuroOne Medical Technologies's current ratio of this year was 4.38365897. NeuroOne Medical Technologies's current ratio of last year was 2.12932501. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NeuroOne Medical Technologies's number of shares in issue this year was 8.485. NeuroOne Medical Technologies's number of shares in issue last year was 5.185. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5.299/9.721
=0.54510853

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3.121/5.759
=0.54193436

NeuroOne Medical Technologies's gross margin of this year was 0.54510853. NeuroOne Medical Technologies's gross margin of last year was 0.54193436. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=9.721/4.457
=2.1810635

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=5.759/5.395
=1.06746988

NeuroOne Medical Technologies's asset turnover of this year was 2.1810635. NeuroOne Medical Technologies's asset turnover of last year was 1.06746988. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+1+1+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeuroOne Medical Technologies has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
NeuroOne Medical Technologies (NMTC) has a Piotroski F-Score of 4 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NeuroOne Medical Technologies and its competitors. This is near median its historical median of 4.00. Over the past decade, NeuroOne Medical Technologies' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, NeuroOne Medical Technologies ranks #455 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.5%.
Is NeuroOne Medical Technologies' Piotroski F-Score too high?
NeuroOne Medical Technologies' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. NeuroOne Medical Technologies' value of 4 is 20% below this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #455 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NeuroOne Medical Technologies has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Piotroski F-Score compare to CTSO and CODX?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #455 out of 805 companies for Piotroski F-Score. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median Piotroski F-Score is 5.00. NeuroOne Medical Technologies' value of 4 is 20% below this benchmark. Historically, NeuroOne Medical Technologies' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, NeuroOne Medical Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.25 — trading 50.6% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Devices & Instruments industry median of 5.00. NeuroOne Medical Technologies' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Piotroski F-Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.25 is trading 50.6% below its estimated GF Value™ of $6.58. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: $6.58 vs. price of $3.25 (50.6% below fair value)
  • GF Score™: 43/100 with 3 warning signs
  • Industry Position: 20% below the Medical Devices & Instruments median (#455 of 805)

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
43GF Score

Get the complete analysis for NMTC

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price
$6.58
GF Value